Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.

S. Hijazi, B. Meller, C. Leitsmann, A. Strauss, J. Meller, C. O. Ritter, J. Lotz, H.-U. Schildhaus, L. Trojan, C. O. Sahlmann, Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga‐PSMA‐positron emission tomography/computerized tomography The Prostate. ,vol. 75, pp. 1934- 1940 ,(2015) , 10.1002/PROS.23091

Warren D. W. Heston, C. Thomas Powell, William R. Fair, Ron S. Israeli, John G. Corr, Expression of the prostate-specific membrane antigen Cancer Research. ,vol. 54, pp. 1807- 1811 ,(1994)

J. J. Morigi, P. D. Stricker, P. J. van Leeuwen, R. Tang, B. Ho, Q. Nguyen, G. Hruby, G. Fogarty, R. Jagavkar, A. Kneebone, A. Hickey, S. Fanti, L. Tarlinton, L. Emmett, Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy The Journal of Nuclear Medicine. ,vol. 56, pp. 1185- 1190 ,(2015) , 10.2967/JNUMED.115.160382

A. Afshar-Oromieh, A. Malcher, M. Eder, M. Eisenhut, H. G. Linhart, B. A. Hadaschik, T. Holland-Letz, F. L. Giesel, C. Kratochwil, S. Haufe, U. Haberkorn, C. M. Zechmann, PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 40, pp. 486- 495 ,(2013) , 10.1007/S00259-012-2298-2

M. J. Evans, P. M. Smith-Jones, J. Wongvipat, V. Navarro, S. Kim, N. H. Bander, S. M. Larson, C. L. Sawyers, Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen Proceedings of the National Academy of Sciences of the United States of America. ,vol. 108, pp. 9578- 9582 ,(2011) , 10.1073/PNAS.1106383108

Ali Afshar-Oromieh, Christian M. Zechmann, Anna Malcher, Matthias Eder, Michael Eisenhut, Heinz G. Linhart, Tim Holland-Letz, Boris A. Hadaschik, Frederik L. Giesel, Jürgen Debus, Uwe Haberkorn, Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 41, pp. 11- 20 ,(2014) , 10.1007/S00259-013-2525-5

Christina Messiou, Gary Cook, Alison HM Reid, Gerhardt Attard, David Dearnaley, Johann S de Bono, Nandita M de Souza, The CT flare response of metastatic bone disease in prostate cancer. Acta Radiologica. ,vol. 52, pp. 557- 561 ,(2011) , 10.1258/AR.2011.100342

M. Eiber, T. Maurer, M. Souvatzoglou, A. J. Beer, A. Ruffani, B. Haller, F.-P. Graner, H. Kubler, U. Haberhorn, M. Eisenhut, H.-J. Wester, J. E. Gschwend, M. Schwaiger, Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy The Journal of Nuclear Medicine. ,vol. 56, pp. 668- 674 ,(2015) , 10.2967/JNUMED.115.154153

Matthew R. Cooperberg, Peter R. Carroll, Trends in Management for Patients With Localized Prostate Cancer, 1990-2013 JAMA. ,vol. 314, pp. 80- 82 ,(2015) , 10.1001/JAMA.2015.6036

Charles J. Ryan, Shreya Shah, Eleni Efstathiou, Matthew R. Smith, Mary-Ellen Taplin, Glenn J. Bubley, Christopher J. Logothetis, Thian Kheoh, Christine Kilian, Christopher M. Haqq, Arturo Molina, Eric J. Small, Phase II Study of Abiraterone Acetate in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant With Serologic Response Clinical Cancer Research. ,vol. 17, pp. 4854- 4861 ,(2011) , 10.1158/1078-0432.CCR-11-0815